TY - JOUR
T1 - Replacement therapy for iron deficiency improves exercise capacity and quality of life in patients with cyanotic congenital heart disease and/or the Eisenmenger syndrome
AU - Tay, Edgar L.W.
AU - Peset, Ana
AU - Papaphylactou, Maria
AU - Inuzuka, Ryo
AU - Alonso-Gonzalez, Rafael
AU - Giannakoulas, Georgios
AU - Tzifa, Aphrodite
AU - Goletto, Sara
AU - Broberg, Craig
AU - Dimopoulos, Konstantinos
AU - Gatzoulis, Michael A.
N1 - Funding Information:
Dr. Edgar Tay is supported by a training scholarship from the Ministry of Health, Singapore. Dr. Rafael Alonso-Gonzalez, MD, has received a research grant from Fundacion Alfonso Martin Escudero, Madrid, Spain. Dr. Giannakoulas was supported by the Hellenic Heart Foundation, DG Education and Culture–LLP Programme–Leonardo Da Vinci Mobility and Hellenic Cardiological Society. Professor Gatzoulis and the Royal Brompton Hospital Adult Congenital Heart Disease Centre have received support from the British Heart Foundation.
PY - 2011/9/15
Y1 - 2011/9/15
N2 - Introduction: Iron deficiency is common in cyanotic congenital heart disease (CHD) and results in reduced exercise tolerance. Currently, iron replacement is advocated with limited evidence in cyanotic CHD. We investigated the safety and efficacy of iron replacement therapy in this population. Methods: Twenty-five iron-deficient cyanotic CHD patients were prospectively studied between August 2008 and January 2009. Oral ferrous fumarate was titrated to a maximum dose of 200 mg thrice-daily. The CAMPHOR QoL questionnaire, 6 minute walk test (6MWT) and cardiopulmonary exercise testing were conducted at baseline and after 3 months of treatment. Results: Mean age was 39.9 ± 10.9 years, 80% females. Fourteen had Eisenmenger syndrome, 6 complex cyanotic disease and 5 Fontan circulation. There were no adverse effects necessitating termination of treatment. After 3 months of treatment, hemoglobin (19.0 ± 2.9 g/dL to 20.4 ± 2.7 g/dL, p < 0.001), ferritin (13.3 ± 4.7 μg/L to 54.1 ± 24.2 μg/L, p < 0.001) and transferrin saturation (17.8 ± 9.6% to 34.8 ± 23.4%, p < 0.001) significantly increased. Significant improvements were also detected in the total CAMPHOR score (20.7 ± 10.9 to 16.2 ± 10.4, p = 0.001) and 6MWT distance (371.7 ± 84.7 m to 402.8.0 ± 74.9 m, p = 0.001). Peak VO 2 remained unchanged (40.7 ± 9.2% to 43.8 ± 12.4% of predicted, p = 0.15). Conclusion: Three months of iron replacement therapy in iron-deficient cyanotic CHD patients was safe and resulted in significant improvement in exercise tolerance and quality of life. Identification of iron deficiency and appropriate replacement should be advocated in these patients.
AB - Introduction: Iron deficiency is common in cyanotic congenital heart disease (CHD) and results in reduced exercise tolerance. Currently, iron replacement is advocated with limited evidence in cyanotic CHD. We investigated the safety and efficacy of iron replacement therapy in this population. Methods: Twenty-five iron-deficient cyanotic CHD patients were prospectively studied between August 2008 and January 2009. Oral ferrous fumarate was titrated to a maximum dose of 200 mg thrice-daily. The CAMPHOR QoL questionnaire, 6 minute walk test (6MWT) and cardiopulmonary exercise testing were conducted at baseline and after 3 months of treatment. Results: Mean age was 39.9 ± 10.9 years, 80% females. Fourteen had Eisenmenger syndrome, 6 complex cyanotic disease and 5 Fontan circulation. There were no adverse effects necessitating termination of treatment. After 3 months of treatment, hemoglobin (19.0 ± 2.9 g/dL to 20.4 ± 2.7 g/dL, p < 0.001), ferritin (13.3 ± 4.7 μg/L to 54.1 ± 24.2 μg/L, p < 0.001) and transferrin saturation (17.8 ± 9.6% to 34.8 ± 23.4%, p < 0.001) significantly increased. Significant improvements were also detected in the total CAMPHOR score (20.7 ± 10.9 to 16.2 ± 10.4, p = 0.001) and 6MWT distance (371.7 ± 84.7 m to 402.8.0 ± 74.9 m, p = 0.001). Peak VO 2 remained unchanged (40.7 ± 9.2% to 43.8 ± 12.4% of predicted, p = 0.15). Conclusion: Three months of iron replacement therapy in iron-deficient cyanotic CHD patients was safe and resulted in significant improvement in exercise tolerance and quality of life. Identification of iron deficiency and appropriate replacement should be advocated in these patients.
KW - Cyanotic congenital heart disease
KW - Exercise capacity
KW - Iron replacement therapy
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=80052695805&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052695805&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2010.05.066
DO - 10.1016/j.ijcard.2010.05.066
M3 - Article
C2 - 20580108
AN - SCOPUS:80052695805
SN - 0167-5273
VL - 151
SP - 307
EP - 312
JO - International Journal of Cardiology
JF - International Journal of Cardiology
IS - 3
ER -